ArticleProteomics. Clinical applications2025
Targeted Proteomic Analysis of Sickle Cell Disease Patients With Elevated Tricuspid Regurgitation Velocity.
Article in Proteomics. Clinical applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma proteome signatures are predictive of mortality in sickle cell disease.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposePulmonary hypertension (PH) is a chronic complication of sickle cell disease (SCD) with limited known biomarkers, beyond increases in plasma brain natriuretic peptide levels. EXPERIMENTAL
designWe conducted a proof-of-concept study to identify serum protein biomarkers that were differentially expressed in SCD patients with elevated tricuspid regurgitation velocity (TRV-a noninvasive marker of PH).
resultsWe found 41 out of 92 target proteins that were significantly different between the nonelevated (TRV ≤ 2.6 m/s; N = 35) and highly elevated TRV group (TRV ≥ 2.9 m/s; N = 35, p < 0.05). Six of them passed a Bonferroni correction (p value < 0.0005), including T-cell surface glycoprotein, lymphotactin, SLAM family member 7, galectin-9, TNF-related apoptosis-inducing ligand receptor 2, and tumor necrosis factor receptor superfamily member 11A. We observed up to a 1.2-fold increase in the high TRV group for these six proteins. These six proteins had a strong positive correlation with serum NT-proBNP levels (a positive control marker elevated in PH [r ≥ 0.44]). Additionally, these markers correlated with other clinical parameters of PH in SCD.
conclusionCirculatory protein markers of the immune response are increased in SCD patients with elevated TRV as compared to those without elevated TRV. SUMMARY: This study demonstrates that the circulatory protein markers of the immune response are increased in SCD patients with elevated TRV compared to those without elevated TRV. These biomarkers may be important tools for risk-stratifying patients with SCD or targets for therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.